Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-08
2007-05-08
Landsman, Robert S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S402000
Reexamination Certificate
active
10720039
ABSTRACT:
The present invention provides a method of transporting a pharmacologically active peptide across the blood brain barrier by administering to a living subject a conjugate molecule of a general class of chimeric hybrid conjugate molecules capable of simultaneous activation of MOR and SPR receptors within the CNS that is intrinsically a function of this class of molecules to permeate the mammalian BBB as an intact chemical entity. Accordingly, the chemical and pharmacological integrity of each of the receptor activating domains functionally enables BBB transport of its covalently bonded reciprocal receptor activating domain. As such, the requirement for an intact chimeric hybrid conjugate molecule as the only viable transport vehicle for equivalent BBB transport of each of its MOR and SPR receptor activation domains distinguishes the present invention as novel and unknown to the literature of CNS analgesic and anti-abuse drugs.
REFERENCES:
patent: 5891842 (1999-04-01), Kream
patent: 6063758 (2000-05-01), Lappi et al.
patent: 6310072 (2001-10-01), Smith et al.
patent: 6759520 (2004-07-01), Carr et al.
patent: 6881829 (2005-04-01), Kream
patent: WO 01/30371 (2001-05-01), None
Wainer BH, et al. Science 176(4039):1143-1145, 1972.
Reuler, et al.,The Chronic Pain Syndrone: Misconceptions&Management, Ann Intern Med. 93:588-596 (1980).
Sriwatankul, et al,Anaylsis of Narcotic Analgesic usage in the Treatment of Postoperative Pain, JAMA 250:926-929 (1983).
Schechter,Pain&Pain Control in Children, Current Problems in Pediatrics 15 (1985).
Goodman & Gilman,The Pharmacological Basis of Therapeutics511 (7thed. 1985).
Foran, et al,A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic, 97 PNAS 13:7521-26 (2001).
Egelton, et al,Transport of Opioid Peptides into the Central Nervous System, J Pharm Sci 1998, 87(11):1433-39.
Borchard,Optimizing oral absorption of peptides using prodrug strategies, J Control Release 1999; 62(1-2):231-38.
Stain-Texier,Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability, Br J Pharmacol 1999; 128(4):917-24.
Merrifield,Solid Phase Synthesis, SCIENCE 232: 241-47 (1986).
Barany, et al,Solid-phase peptide synthesis; a silver anniversary report, Int'l J Peptide Protein Res 30:705-39 (1987).
Kent,Chemical Synthesis of Peptides and Proteins, Ann Rev Biochem 57:857-989 (1988).
Kaiser, et al,Peptide&Protein Synthesis by Segment Synthesis-Condensation, SCIENCE 243:187-98 (1989).
Kream,Substance P markedly potentiates the antinocicpetive effects of morphine sulphate administered at the spinal level, 90 PNAS 5564-68 (1993).
Masczynska, et al,Alternative forms of interaction of substance P and opioids innocicpetice transmission, Ltrs Peptide Sci 298, 5:395-98 (1998).
Masczynska, et al,Dual Functional Interactions of Substance P Opioids in Nociceptive Transmission, Analgesia 3:259-68 (1998).
Watson, et al,Tissue Selectivity of Substance P Alkyl Esters Suggesting Multiple Receptors, Euro J Pharmacol 87:77-84 (1983).
Sizheng, et al,Opioid and neurokinin activities of substance P fragments and their analogs, Euro J Pharmacol 193:209-15 (1991).
Lipkowski, et al,An Approach to the Self Regulatory Mechanism of Substance P Actions, 33 Life Sciences141-44 (1983).
Foran, et al,Inhibition of Morphine tolerance Development by a Substance P-Opioid Peptide Chimera, J Pharmacol & Ex Thera 295:3:1142-48 (2000).
Lipkowski, et al,Opioid Peptide Analogues: Reconsideration as a Potentially New Generation of Analgesics, Polish J Chem, 68:907 12 (1994).
Misterek, et al,Spinal Co-Administration of Peptide Substnace P Antagonist Increases Antinociceptive Effect of the Opioid Peptide Biphalin, 54 Life Sciences, 14:939-44 (1994).
Foran, et al.,Chimeric Peptide for the Treatment of Acute&Chronic Pain, ANESTHESIOLOGY 91:3A:A944 (1999).
Langel, et al,Design of chimieric peptide ligands to galanin receptors and substance P receptors, Intl J Peptide & Protein Res 39:6:516-533 (1992).
Cavagnero, et al,Delta opioid Receptor Selectivity Ligands, 49 Life Sciences 495-503 (1991).
Carr, et al,Mechanisms of Opioid Analgetic Actions, 1 Principles & Practice of Anesthesiology, Ch 32 (1993).
Lipkowski, et al, Neuropeptides: Peptide and Nonpeptide Analogs, Peptides: Synthesis, Structures and Applications. 1995, pp. 287-320. Academic Press.
Chimeracom, LLC
Landsman Robert S.
LandOfFree
Method of transporting a chimeric hybrid molecule across the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of transporting a chimeric hybrid molecule across the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of transporting a chimeric hybrid molecule across the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3804166